Search
GTS-21
go.drugbank.com/drugs/DB05708Investigationalrelated and memory related tasks (Kitagawa, et al. … GTS-21 has been studied in multiple Phase I studies in healthy volunteers and one Phase I/II study in schizophrenic patients. In all studies, the compound was well tolerated.
Sodium copper chlorophyllin
go.drugbank.com/drugs/DB16522InvestigationalSodium copper chlorophyllin (SCC) is a water-soluble and bright green mixture derived from natural chlorophyll that has potential antimutagenic and antioxidant properties . This compound is used as a food colorant and supplement . SCC of...
Categories: Compounds used in a research, industrial, or household settingSCIB1
go.drugbank.com/drugs/DB18439InvestigationalIt consists of plasmid DNA molecules that express a modified antibody in human cells, working to stimulate the patient's T cells to have a stronger reaction against melanoma cells. … SCIB1 is an investigational cancer vaccine being developed by Scancell Ltd. It is being investigated for the treatment of melanoma.
PYM50018
go.drugbank.com/drugs/DB05126ExperimentalIt is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease). … In pre-clinical models, PYM50018 has been observed to protect against neuronal damage, increase neurite outgrowth, reverse oxidative damage and reverse neuronal apoptosis in vitro.
Agkistrodon piscivorus antivenin
go.drugbank.com/drugs/DB13894ApprovedIt is intravenously (IV) administered to limit/prevent systemic toxicity [FDA label]. … The cottonmouth, Agkistrodon piscivorus, is a large, venomous snake in the pit viper subfamily (Crotalinae).
Deanol
go.drugbank.com/drugs/DB13352InvestigationalIt has been also used as an ingredient in skin care, and in cognitive function- and mood-enhancing products. … It holds tertiary amine and primary alcohol groups as functional groups.
AZD 3355
go.drugbank.com/drugs/DB05404InvestigationalIt is developed by AstraZeneca and is currently in phase I/II trials.
Bisegliptin
go.drugbank.com/drugs/DB06127InvestigationalIt is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion
KOS-2187
go.drugbank.com/drugs/DB05946ExperimentalKOS-2187, a novel erythromycin-based motilin agonist, or motilide, as a clinical candidate for the treatment of gastrointestinal motility disorders such as gastroparesis and gastroesophageal reflux disease (GERD).
Afimoxifene
go.drugbank.com/drugs/DB04468InvestigationalIt is being developed by Ascent Therapeutics.